Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03074513 · ClinicalTrials.gov registry record · Phase 2
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
A Phase 2 study of Neuroendocrine Carcinoma and Pancreatic Neuroendocrine Tumor, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 133
- Enrollment target
- 1
- Study location
NCT03074513 is a Phase 2 study of Neuroendocrine Carcinoma and Pancreatic Neuroendocrine Tumor that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 133 participants, below the 271-participant average among 13 other Neuroendocrine Carcinoma trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03074513, a Phase 2 study of Neuroendocrine Carcinoma and Pancreatic Neuroendocrine Tumor, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 133 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with rare solid tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Conditions Studied
Interventions
- DRUG Atezolizumab
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Bevacizumab
- OTHER Pharmacological Study
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2017-03-03 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03074513
The ClinicalTrials.gov registry entry for NCT03074513 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 133 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 271-participant average among 13 other Neuroendocrine Carcinoma trials with a reported enrollment target (51% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Neuroendocrine Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Atezolizumab is the first listed.
NCT03074513 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03074513 about?
NCT03074513 is a clinical study titled "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors". This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with rare solid tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells t...
What is the current status of trial NCT03074513?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 133 participants. The study started on 2017-03-03. Estimated completion is 2027-09-30.
What conditions does trial NCT03074513 study?
This clinical trial studies the following conditions: Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Tumor, Recurrent Peritoneal Malignant Mesothelioma, Appendix Adenocarcinoma, Human Papillomavirus-Related Cervical Squamous Cell Carcinoma.
What interventions are being tested in trial NCT03074513?
The interventions under investigation include: Atezolizumab (DRUG), Laboratory Biomarker Analysis (OTHER), Bevacizumab (BIOLOGICAL), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT03074513?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03074513 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
RECRUITING · Phase 2
-
Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
ACTIVE NOT RECRUITING · Phase 2
-
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
ACTIVE NOT RECRUITING · Phase 2
-
RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
COMPLETED · Phase 2
-
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.